The National Health Insurance Authority says it has expanded the financial protection it offers cancer patients, shielding eligible enrollees from 80 per cent of the cost of selected cancer medicines and raising support for radiotherapy and diagnostic tests.
The authority set out the measures in a statement issued on Sunday to mark Breast Cancer Awareness Month. At the centre of the package is a cost-sharing arrangement with the pharmaceutical company Roche, under which Roche bears half the cost of listed oncology medicines, the NHIA pays 30 per cent, and the patient covers the remaining 20 per cent.
For radiotherapy, the authority says it has introduced support ranging from N400,000 to full coverage for eligible patients. Other covered services include mammography, CT and MRI scans, bone scans, and cancer-related laboratory and diagnostic tests, with screening, surgery, chemotherapy and follow-up care available depending on the benefit package.
The NHIA Director-General, Dr Kelechi Ohiri, argued that the measures reflect a shift in how the scheme judges its own performance. “The critical measure of the insurance system should no longer be the number of Nigerians carrying insurance records, but whether those records provide meaningful protection when illness strikes,” he said.
That framing responds to a long-standing criticism of health insurance in Nigeria, where rising enrolment has not always translated into affordable care at the point of need. The authority says more than 23 million Nigerians are now enrolled, up from about 16 million at the start of the current administration, giving it a wider pool through which to extend interventions for high-cost diseases.
The cost of cancer care is what makes the intervention consequential. Independent accounts of treatment in Nigeria put individual chemotherapy doses at between N150,000 and N500,000, and radiotherapy at between N1.5m and N2m, with comprehensive breast cancer treatment running into millions more. Health researchers have estimated that more than 70 per cent of cancer care in the country is paid for out of pocket, which pushes many families into debt or interrupted treatment.
Set against those figures, the scope of the relief is real but bounded. The N400,000 ceiling on radiotherapy support, for instance, covers only a fraction of a bill that can reach N2m, a limitation some commentators have already flagged. The authority itself acknowledged that the interventions are not sufficient on their own to address the scale of the burden.
On that burden, the NHIA cited figures from the Global Cancer Observatory putting breast cancer in Nigeria at an estimated 32,278 new cases and 16,332 deaths. Those numbers come from the observatory’s 2022 estimates rather than a confirmed annual count, though they remain the most widely referenced national figures and rank Nigeria among the highest for breast cancer deaths in Africa. Breast cancer remains the most commonly diagnosed cancer among Nigerian women.
The authority also pointed to a Federal Government disclosure in July 2026 that Nigeria accounts for about 10.5 per cent of Africa’s cancer burden, placing it among the three most affected countries on the continent. It said advanced treatment abroad is beyond the reach of most households, while locally available care can itself be expensive, leaving families exposed to prolonged financial pressure.
The NHIA presented its measures as complementary to a wider Federal Government effort under the Federal Ministry of Health and Social Welfare. Nigeria is implementing the National Cancer Control Plan 2026 to 2030, which spans prevention, early detection, diagnosis, treatment, survivorship, research and the expansion of the oncology workforce.
Part of that effort involves infrastructure. The authority said six Oncology Centres of Excellence are being upgraded, with centres at the University College Hospital, Ibadan; the University of Benin Teaching Hospital; the University of Nigeria Teaching Hospital, Enugu; and the Ahmadu Bello University Teaching Hospital, Zaria, already operational with specialised equipment, including brachytherapy machines.
Other programmes run alongside the insurance intervention. The authority cited the Cancer Access Partnership, through which it said 27 anti-cancer medicines in 48 formulations are supplied across 14 federal tertiary hospitals, and the Cancer Health Fund for indigent patients with breast, cervical and prostate cancers.
Earlier figures from the authority indicate the drug cost-sharing programme is still at an early stage of reach. At its launch, the NHIA said more than 200 cancer patients across seven tertiary institutions had benefited from the medicine arrangement, a modest figure against a patient population measured in tens of thousands.
Marking the start of the awareness month, the authority urged women to watch for changes in their breasts, seek medical advice promptly and take up screening where available. It said reducing deaths and financial hardship from breast cancer would ultimately require stronger public awareness, earlier diagnosis, wider access to treatment and financing that can keep illness from tipping households into distress.